{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:23Z","timestamp":1761710123010,"version":"3.37.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015660","name":"UCB Pharma Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.yebeh.2024.109989","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T07:21:40Z","timestamp":1725002500000},"page":"109989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy"],"prefix":"10.1016","volume":"159","author":[{"given":"Mark Kristof","family":"Farkas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Makedonska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Beller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Bourikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Dimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florin","family":"Floricel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus Eric","family":"Pina-Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.109989_b0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14656566.2010.517194","article-title":"Pharmacotherapy for children and adolescents with epilepsy","volume":"12","author":"Verrotti","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2024.109989_b0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/epi4.12356","volume":"4","author":"Auvin","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.109989_b0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/dmcn.12432","article-title":"Cognitive development in children with new onset epilepsy","volume":"56","author":"Rathouz","year":"2014","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/dmcn.12549","article-title":"Longitudinal trajectories of behavior problems and social competence in children with new onset epilepsy","volume":"57","author":"Zhao","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","article-title":"Cognitive effects of antiepileptic drugs","volume":"4","author":"Park","year":"2008","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/JCP.0b013e318253a186","article-title":"Behavioral adverse effects of antiepileptic drugs in epilepsy","volume":"32","author":"Eddy","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2024.109989_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13760-016-0734-y","article-title":"The importance of assessing behaviour and cognition in antiepileptic drug trials in children and adolescents","volume":"117","author":"Lagae","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2024.109989_b0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.109989_b0045","unstructured":"Vimpat\u00ae (lacosamide) Prescribing Information, https:\/\/www.ucb-usa.com\/vimpat-prescribing-information.pdf; 2023 [accessed 08 April 2024]."},{"key":"10.1016\/j.yebeh.2024.109989_b0050","unstructured":"Vimpat\u00ae (lacosamide) Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/documents\/product-information\/vimpat-epar-product-information_en.pdf; 2024 [accessed 08 April 2024]."},{"key":"10.1016\/j.yebeh.2024.109989_b0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - an open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109989_b0060","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000008126","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"Farkas","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109989_b0065","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/epi.17741","article-title":"Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: phase 2, open-label exploratory trial","volume":"64","author":"Auvin","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0070","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acn3.52004","article-title":"Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures","volume":"11","author":"Makedonska","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0075","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2024.109989_b0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/epi4.12682","article-title":"Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2\/3 trial","volume":"8","author":"Farkas","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.109989_b0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.yebeh.2014.09.074","article-title":"Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years","volume":"41","author":"Rosenfeld","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ane.12451","article-title":"Long-term adjunctive lacosamide treatment in patients with partial-onset seizures","volume":"133","author":"Rosenow","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2024.109989_b0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jpc.14156","article-title":"Lacosamide in children with drug-resistant epilepsy","volume":"55","author":"R\u00fcegger","year":"2019","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.yebeh.2024.109989_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108598","article-title":"Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: therapy optimization as emerging from an observational study","volume":"128","author":"Pozzi","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108614","article-title":"Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: a cohort study","volume":"129","author":"Ishikawa","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0115","article-title":"Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy","volume":"21","author":"Driessen","year":"2023","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.yebeh.2024.109989_b0120","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: a single-center observational study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107814","article-title":"Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China","volume":"117","author":"Zhao","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109989_b0135","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/acn3.51999","article-title":"Pitfalls of using video-EEG for a trial endpoint in children aged <4 years with focal seizures","volume":"11","author":"Bozorg","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1528-1157.1999.tb00833.x","article-title":"Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0145","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.53.8.1724","article-title":"A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children","volume":"53","author":"Duchowny","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109989_b0150","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.52.7.1338","article-title":"A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children","volume":"52","author":"Elterman","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109989_b0155","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1212\/WNL.54.12.2237","article-title":"Adjunctive therapy with oxcarbazepine in children with partial seizures","volume":"54","author":"Glauser","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109989_b0160","first-page":"269","article-title":"Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study","volume":"43","author":"Appleton","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0165","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109989_b0170","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/epi.12233","article-title":"A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy","volume":"54","author":"Guerrini","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0175","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/epi.12548","article-title":"Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial","volume":"55","author":"Guerrini","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/epi.16413","article-title":"Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures","volume":"61","author":"Fogarasi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106962","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial","volume":"105","author":"Kirkham","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0190","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/epi.16466","article-title":"Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: a double-blind, placebo-controlled, video-electroencephalographic trial","volume":"61","author":"Mann","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejpn.2019.11.007","article-title":"Safety and tolerability of adjunctive brivaracetam in children with focal seizures: interim analysis of pooled data from two open-label trials","volume":"25","author":"Patel","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.109989_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107458","article-title":"Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures","volume":"112","author":"Sankar","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0205","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1111\/epi.17754","article-title":"Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open-label, follow-up trial","volume":"64","author":"Lagae","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0210","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yebeh.2011.02.005","article-title":"Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy","volume":"20","author":"Gavatha","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109989_b0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain","volume":"12","author":"Casas-Fernandez","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.yebeh.2024.109989_b0220","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2024.109989_b0225","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial","volume":"91","author":"Vossler","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2024.109989_b0230","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1055\/s-0042-1758366","article-title":"Use of lacosamide in children: experience of a tertiary medical care center in Brazil","volume":"80","author":"Rom\u00e3o","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.yebeh.2024.109989_b0235","unstructured":"Worrall G. Common cold. Can Fam Physician 2007;53:1735\u20136."},{"key":"10.1016\/j.yebeh.2024.109989_b0240","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109989_b0245","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40263-015-0281-8","article-title":"Antiepileptic drug treatment in children with epilepsy","volume":"29","author":"Rosati","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2024.109989_b0250","doi-asserted-by":"crossref","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981;22: 489\u2013501. https:\/\/doi.org\/10.1111\/j.1528-1157.1981.tb06159.x.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"10.1016\/j.yebeh.2024.109989_b0255","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024003706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024003706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:15:43Z","timestamp":1726373743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024003706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":51,"alternative-id":["S1525505024003706"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109989","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109989"}}